184910-20-1 Usage
Description
(4-bromo-2,6-difluorophenyl)trimethylsilane, with the chemical formula C9H10BrF2Si, is a colorless liquid chemical compound. It features a phenyl ring with a bromine atom and two fluorine atoms, as well as three methyl groups attached to a silicon atom. (4-broMo-2,6-difluorophenyl)triMethylsilane serves as a crucial building block for the synthesis of organofluorine compounds and is valued for its applications across various industries.
Uses
Used in Pharmaceutical Industry:
(4-bromo-2,6-difluorophenyl)trimethylsilane is used as a reagent for the synthesis of organofluorine compounds, which are essential in the development of new pharmaceuticals. These compounds often possess enhanced biological activity and chemical stability, making them valuable for creating innovative drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical sector, (4-bromo-2,6-difluorophenyl)trimethylsilane is utilized as a reagent for the production of organofluorine compounds that are integral to the development of new pesticides and herbicides. These compounds can enhance the effectiveness of these chemicals, leading to better crop protection and increased agricultural productivity.
Used in Material Science:
(4-bromo-2,6-difluorophenyl)trimethylsilane is employed as a building block in the development of novel materials with unique properties. Its incorporation into these materials can lead to improved performance characteristics, such as increased stability, enhanced chemical resistance, or superior mechanical properties.
Used as a Catalyst:
(4-broMo-2,6-difluorophenyl)triMethylsilane also serves as a catalyst in various chemical reactions, facilitating the conversion of reactants to products and increasing the overall efficiency of the reaction process. Its use as a catalyst can lead to more sustainable and cost-effective synthetic routes for the production of various chemicals and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 184910-20-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,4,9,1 and 0 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 184910-20:
(8*1)+(7*8)+(6*4)+(5*9)+(4*1)+(3*0)+(2*2)+(1*0)=141
141 % 10 = 1
So 184910-20-1 is a valid CAS Registry Number.
184910-20-1Relevant articles and documents
BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS
-
Page/Page column 122, (2021/09/26)
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
Fluorine-flanked congested sites: Minimal, though perceptible buttressing effects on the proton mobility of arenes
Heiss, Christophe,Leroux, Frederic,Schlosser, Manfred
, p. 5242 - 5247 (2007/10/03)
(2,6-Difluorophenyl)trimethylsilane, -triethylsilane and -triisopropylsilane undergo sec-butyllithium-mediated metalation at the 3- and 4-position (ortho and meta relative to the halogen) in ratios of 99.6:0.4, 98:2 and 95:5, respectively. The steric pressure transmitted by the fluorine atoms can be increased if the trialkylsilyl group is locked up on the other side by a relatively voluminous substituent. Whereas (2,6-difluorophenyl)triethylsilane is attacked by lithium 2,2,6,6-tetramethylpiperidide under deprotonation of the 4- and 5-position in a ratio of 99.4:0.6, the proportion of "ortho"/ "meta" metalation changes to 84:16 when (2-bromo-6-fluorophenyl) triethylsilane acts as the substrate. Wiley-VCH Verlag GmbH & Co. KGaA, 2005.
Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use
-
Page 40, (2010/02/03)
Aminothiazole compounds with mono-/di-substituted benzamide are represented by the Formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and pharmaceutically acceptable salts of said metabolites are described. These agents modulate and/or inhibit the cell proliferation and activity of protein kinases and are useful as pharmaceuticals for treating malignancies and other disorders.
